Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unadjuvanted RSV Maternal Vaccine in High Risk Pregnant Women
NCT04980391Phase 3Terminated
- Sponsor
- GSK
- Start
- Aug 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of GSK3858279 in respiratory syncytial virus infection (RSV) (2 arms), sponsored by GSK. Primary endpoints: Percentage of Maternal Participants Reporting Any Solicited Administration Site Events, Percentage of Maternal Participants Reporting Any Solicited Systemic Events and 9 more. Started Aug 2021; status: terminated.
02
Drugs
GSK3858279
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04980391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04980391.